Hollandbio welcomes DGr Pharma as a new member
Hollandbio connects, represents and supports the Dutch biotech sector. With more than 290 members – from start-ups and scale-ups to established companies active in health, food and the biobased economy – we work together to strengthen the Dutch life sciences ecosystem. Today, we are pleased to welcome DGr Pharma as our newest member. DGr Pharma, based in Breda, is an internationally operating consultancy and contract research organization, which leverages the expertise and experience of its highly-skilled, multi-disciplinary workforce to accelerate drug development. By joining hollandbio, they want to meet innovative companies and to help them bring their products to the market.
“Our unique concentration of multidisciplinary experts – combined with a direct and pragmatic approach – presents sponsors with flexible service options to cope with business and regulatory requirements. Another strength is the flat organizational structure of DGr Pharma which encourages direct communication. This culture empowers experts with direct involvement in the decision-making process and allows sponsors easy and fast access to their expertise. We have an extensive track record, especially in the areas of oncology and infectious diseases and helped to bring more than 30 molecules successfully to the clincic and some of them even to the market.”
“Our CMC, non-clinical and clinical consultants can support every step in your drug development program from lead selection up to Phase IIa clinical trials. Whether you want support to successfully convert your lead molecule to a pharmaceutical product, input on your development strategy, assistance in preparation of meetings with regulatory agencies, advice on a single study, or whether you want us to manage your entire program, we will help realize a fast and high-quality drug development process.”
“Besides our consultancy services, we offer GLP certified PK/TK data analysis according to OECD guidelines using in-house validated Phoenix WinNonlin and SAS routines for both non-clinical and clinical studies. Our expert PK/TK data analysts provide high quality data for both small biotech, as well as large pharma in compliance with regulatory (EU and US) requirements. We are proud to say that our analyses have never led to regulatory questions.”